← Eichor
Study identifier: NCT07710287 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Evaluation of the Accuracy of Immunostaining of Claudin 2 to Detect Active or Inactive Inflammation in Endoscopic Biopsies of IBD

Condition: Ulcerative Colitis (UC) · Crohn Disease  ·  Sponsor: IRCCS Policlinico S. Donato

PhaseN/A
Planned participants100
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

In view of the increasing evidence of the importance of mucosal healing as a combination of endoscopic and histologic healing, and the complexity and lack of complete agreement of the evaluation of histologic healing in IBD, the aim of this study will be to evaluate the accuracy of a new methodology, the immunostaining for Claudine 2 as compared to others standard well-accepted scoring for histologic activity in IBD. The aim is compare the accuracy of this methodology and in addition the correlation with outcomes (i.e. relapse, hospitalization, surgery).

This description comes directly from the study's public registry record.

Talk to the study team

Vito Annese, Prof. PI  ·  0039 3388261812  ·  vitoannese1@gmail.com

Antonella Bianchi, Study coordinator  ·  0039 025277  ·  antonella.bianchi2@gruopposandonato.it

Always discuss trial participation with your own doctor first.

Locations (1)

Gastroenterology IRCCS San Donato PoliclinicSan Donato Milanese, Mi, ItalyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07710287